Main
Gastric adenocarcinoma, cancer, HER2-negative, adenocarcinoma, gastroesophageal junction adenocarcinomas
GASTRIC ADENOCARCINOMA, CANCER, ADENOCARCINOMA, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, CYTOTOXICITY
Gastric adenocarcinoma is the fifth most commonly diagnosed cancer worldwide, and incidence of gastroesophageal junction adenocarcinomas has markedly increased in the last few decadesThe combination of targeted therapies or immunotherapies with chemotherapy can improve overall survival (OS) in some patients with metastatic diseaseCLDN18.2 is a tight junction protein exclusively expressed in normal gastric mucosa cells and is retained in most G/GEJ adenocarcinomasZolbetuximab is a first-in-class immunoglobulin G1 monoclonal antibody that targets CLDN18.2 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in CLDN18.2-positive G/GEJ adenocarcinoma cellsHere we report the primary analysis of GLOW, a global, randomized, double-blind, phase 3 study, which evaluated the efficacy and safety of first-line treatment with zolbetuximab plus CAPOX compared to placebo plus CAPOX in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma.